loader2
Partner With Us NRI

J B Chemicals & Pharmaceuticals Ltd share Price Today

Company details

1,778.00
1,810.30
875.00
1,940.00
6M Return 33.61%
1Y Return 67.96%
Mkt Cap.(Cr) 27,721.09
Volume 212,672
Div Yield 0.50%
OI
-
OI Chg %
-
Volume 212,672

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

J B Chemicals & Pharmaceuticals announced Q3FY24 & 9MFY24 results:

  • JB Pharma registered revenue of Rs 845 crore in Q3FY24 (YoY growth of 7%) and Rs 2,622 crore in 9MFY24 (YoY growth of 10%)
    • Overall revenue growth impacted by strategic choices made in international business especially South Africa
    • Excluding South Africa business, revenue grew by 10% in Q3FY24 and 14% in 9MFY24
  • Domestic formulations business continued its momentum recording growth of 14% in Q3FY24 as well as in 9MFY24
    • Our chronic portfolio continues to outpace market growth led by key brands
  • In Q3FY24, International business revenue declined by 1% to Rs 383 crore due to the South Africa business
    • In 9MFY24, International business revenue was at Rs 1,190 crore (YoY growth of 6%)
  • Operating EBITDA was Rs 235 crore in Q3FY24 (YoY growth of 22%) and Rs 729 crore in 9MFY24 (YoY growth of 25%)
    • Operating EBITDA margin was 27.8% in Q3FY24 (YoY improvement of 350 bps) and 27.8% in 9MFY24 (YoY improvement of 330 bps)
  • Gross Margin was 67.6% in Q3FY24 (YoY improvement of 530 bps) and 66.4% in 9MFY24 (YoY improvement of 380 bps)
    • Improvement in gross margins is primarily due to cost optimization and favorable product mix
  • Depreciation increased by 21% to Rs 34 crore in Q3FY24 on account of acquired brands
  • ESOP expenses were Rs 12 crore in Q3FY24 as compared to Rs 7 crore in Q2FY24
  • Other expenses increased by 8% in Q3FY24 to Rs 196 crore due to higher freight costs on account of geo-political issues
  • Net Profit improved by 26% in Q3FY24 and 32% in 9MFY24

Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “Our focus on growing the domestic business ahead of the market continues, as reflected in the Q3 performance. The business once again stands out in this quarter. For CY2023, we are the fastest growing company within IPM amongst the top 25 pharma companies. We are excited about our recent Ophthalmology foray which has brought some of the biggest brands in that area into the JB family. The ophthalmology segment holds great promise as we expect this market to grow in mid-teens and consistently outperform IPM growth.

In the international division, the formulations business is stable. Our order book for the CDMO business is looking good for forthcoming quarters. Our approach to developing progressive portfolios is on track, resulting in a positive impact for the exports branded generics business.”

Result PDF

View Other Company Results

J B Chemicals & Pharmaceuticals Ltd shares SWOT Analysis

Strengths (6)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Company with Low Debt

Weakness (6)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (3)

  • Promoter decreasing their shareholding
  • Companies with growing costs YoY for long term projects
  • High PE (PE > 40)

Resistance and support

R1 1,806.2
R2 1,824.4
R3 1,838.5
Pivot

1,792.08

S1 1,773.9
S2 1,759.8
S3 1,741.6
EMA SMA
1,723.5
1,670.8
1,612.6
1,494.7
1,708.7
1,658.5
1,619.9
1,496.2
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 1693.8 104241 BSE
BNP PARIBAS ARBITRAGE Block Sell 2024-01-25 1693.8 104241 BSE
THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDEXFD A SERIES OF V I E I F Bulk Purchase 2020-09-18 1121.89 706756 NSE
Name Category Shares
TAU INVESTMENT HOLDINGS PTE. LTD. PROMOTER 53.78%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

J B Chemicals & Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) J B Chemicals & Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Divis Laboratories Ltd
Price 1,787.95 1,540.10 1,354.85 6,016.10 3,737.50
% Change 0.47 1.14 0.68 1.23 1.79
Mcap Cr 27,721.09 369,521.58 109,383.81 100,353.96 99,219.04
Revenue TTM Cr 3,149.28 43,885.68 15,790.60 24,669.70 7,767.51
Net Profit TTM Cr 410.01 8,560.84 2,513.47 4,507.30 1,823.38
PE TTM 53.68 38.94 27.47 18.96 70.43
1 Year Return 67.96 54.71 48.57 22.54 11.81
ROCE 22.41 16.79 14.76 25.99 19.30
ROE 17.77 16.46 10.66 21.21 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 2,480.33 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 18,396.48 -4,381.83
LAST 3M 82,644.28 31,619.26
LAST 6M 141,441.37 66,162.53
LAST 12M 215,515.77 196,008.04

J B Chemicals & Pharmaceuticals Ltd Information

Stock PE (TTM)
53.68
Promoter Holding
53.83%
Book Value
175.0529
ROCE
22.41%
ROE
17.77%
Description
  • JB Chemicals and Pharmaceuticals Ltd is a major player in the Indian pharmaceutical industry. It manufactures bulk drugs, chemicals, APIs, and a range of pharmaceutical products. It has five manufacturing facilities in Belapur, Thane, Ankleshwar, Panoli, and Daman. The majority of the company’s sales come from products such as Metrogyl, Rantac, and cardiac care medicines. The company also manufactures products for a wide range of therapeutic categories like gastroenterology, dermatology, hypertension, pharmacovigilance, and nicotine replacement therapy. Incorporated in 1976 in Maharashtra, JB Chemicals and Pharmaceuticals Ltd exports to 40 countries across the globe.

    The company is listed on the Bombay Stock Exchange with code 506943 and the National Stock Exchange with the symbol JBCHEPHARM. On November 22, 2022, JB Chemicals and Pharmaceuticals Ltd had a market capitalisation of Rs 16,131 crore.

    On November 22, 2022, JB Chemicals and Pharmaceuticals Ltd share price closed at Rs 2,043.95 per share, down by 2.01% from the open price of Rs 2,089.40. JB Chemicals and Pharmaceuticals Ltd’s share prices have increased by 430.04% over the past three years and 23.62% in the past 12 months. On November 22, 2022, the share’s 52-week high was Rs 2,150, and the 52-week low was Rs 1,342.20. 

    The company earned Rs 809 crore in revenue in the September 2022 quarter. It has been the best quarter of the year for the company. It made a profit of Rs 111 crore, which is 11% higher than its profit in the September 2021 quarter.

    Promoters hold 53.96% of the company’s shares, retail and others have a 19.31% stake, and 15.40% of the shares are held by mutual funds.

    Nikhil Chopra is the company’s CEO and the whole-time director, Dilip Singh Rathore is the president of India business, Kunal Khanna is the president of operations, Lakshay Kataria is the CFO, Bhushan Sachdev is the vice president of the supply chain department, and Bharat Dhanani is the vice president of operations.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code:  56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-2482 2222/2493 0918
Email : investorelations:jbpharma.com; secretarial:jbpharm
Website : http://www.jbpharma.com
Registrar

Datamatics Financial Services

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 506943
NSE Code : JBCHEPHARM
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE572A01036

FAQ’s on J B Chemicals & Pharmaceuticals Ltd Shares

You can buy J B Chemicals & Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy J B Chemicals & Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Apr 22, 2024 03:54 PM the closing price of J B Chemicals & Pharmaceuticals Ltd was ₹ 1,787.95.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Apr 22, 2024 03:54 PM, the market cap of J B Chemicals & Pharmaceuticals Ltd stood at ₹ 27,721.09.

The latest PE ratio of J B Chemicals & Pharmaceuticals Ltd as of Apr 22, 2024 03:54 PM is 53.68

The latest PB ratio of J B Chemicals & Pharmaceuticals Ltd as of Apr 22, 2024 03:54 PM is 0.10

The 52-week high of J B Chemicals & Pharmaceuticals Ltd share price is ₹ 1,940.00 while the 52-week low is ₹ 875.00

Download Our

Download App
market app